NEW DELHI, Sept 23 (Reuters) - India’s Sun Pharmaceutical Industries said on Tuesday it had approval from the U.S. Food and Drug Administration to market generic versions of Paraplatin, which is indicated for the treatment of ovarian cancer.
NEW DELHI, Sept 23 (Reuters) - India’s Sun Pharmaceutical Industries said on Tuesday it had approval from the U.S. Food and Drug Administration to market generic versions of Paraplatin, which is indicated for the treatment of ovarian cancer.
